Fabino Life Sciences (BOM:543444) Debt-to-EBITDA : 4.34 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Fabino Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fabino Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹0.0 Mil. Fabino Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹11.0 Mil. Fabino Life Sciences's annualized EBITDA for the quarter that ended in Sep. 2023 was ₹2.5 Mil. Fabino Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 4.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Fabino Life Sciences's Debt-to-EBITDA or its related term are showing as below:

BOM:543444' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.45 Med: 4.76 Max: 7.88
Current: 7.09

During the past 5 years, the highest Debt-to-EBITDA Ratio of Fabino Life Sciences was 7.88. The lowest was 0.45. And the median was 4.76.

BOM:543444's Debt-to-EBITDA is ranked worse than
86.49% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs BOM:543444: 7.09

Fabino Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Fabino Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fabino Life Sciences Debt-to-EBITDA Chart

Fabino Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

7.88

3.39

4.76

0.45

7.13

Fabino Life Sciences Semi-Annual Data
	Mar19	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial			N/A	N/A	0.42	7.13	4.34

Competitive Comparison of Fabino Life Sciences's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Fabino Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fabino Life Sciences's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fabino Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fabino Life Sciences's Debt-to-EBITDA falls into.

Fabino Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fabino Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	4.061)	/	0.57
	=	7.12

Fabino Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	10.978)	/	2.528
	=	4.34

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Fabino Life Sciences (BOM:543444) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Fabino Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fabino Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Fabino Life Sciences (BOM:543444) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Murthal Road,, Shubham Garden, Jeevan Vihar Extension Near, Sonipat, HR, IND, 131001

Website

https://www.fabinolife.com

Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.

Fabino Life Sciences (BOM:543444) Headlines

No Headlines